View Older Stories View More Recent Stories

Apr 15, 2026 08:30AM Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Mar 3, 2025 08:30AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Sep 30, 2024 08:30AM Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
Sep 26, 2024 08:33AM Allogene Therapeutics (ALLO) to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases
Sep 26, 2024 08:30AM Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheum
Aug 8, 2024 08:30AM Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Aug 7, 2024 04:02PM Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 
Jul 31, 2024 08:30AM Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
Jul 1, 2024 08:30AM Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Tr
Jun 20, 2024 08:30AM Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell
May 23, 2024 08:30AM Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
May 13, 2024 04:01PM Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
May 6, 2024 08:30AM Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Apr 26, 2024 08:32AM Allogene Therapeutics (ALLO) Announces $15M Grant in California for Development of an Allogeneic CAR T in Renal Cell Carcinoma
Apr 26, 2024 08:30AM Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Apr 26, 2024 08:30AM Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Apr 9, 2024 08:30AM Allogene Therapeutics Announces Q2 Investor Conference Participation
Mar 12, 2024 08:30AM Allogene Therapeutics (ALLO) and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement
Mar 12, 2024 08:30AM Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Mar 5, 2024 08:30AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Feb 16, 2024 08:30AM Allogene Therapeutics (ALLO) to Restate Previously Filed Financial Statements
Feb 16, 2024 08:30AM Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Ventur
Jan 16, 2024 04:05PM Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Jan 4, 2024 04:16PM Allogene Therapeutics (ALLO), Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3
Jan 4, 2024 04:15PM Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lym
Jan 4, 2024 04:08PM Allogene Therapeutics (ALLO) Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3
Jan 4, 2024 04:05PM Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Jan 4, 2024 04:05PM Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Jan 3, 2024 04:05PM Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 11, 2023 04:14AM Allogene Therapeutics (ALLO) Presents Safety Data of ALLO-647
Dec 9, 2023 12:00PM Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
Dec 1, 2023 08:30AM Allogene Therapeutics Announces Participation in December Investor Conference
Nov 3, 2023 12:02PM Allogene Therapeutics (ALLO) Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2
Nov 3, 2023 12:00PM Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
Nov 3, 2023 12:00PM Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
Nov 2, 2023 04:02PM Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
Nov 2, 2023 04:02PM Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
Nov 2, 2023 09:00AM Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
Oct 30, 2023 08:30AM Allogene Therapeutics Announces Participation in November Investor Conferences
Oct 26, 2023 08:30AM Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
Oct 16, 2023 08:33AM Allogene Therapeutics (ALLO) Appoints Geoffrey Parker as Chief Financial Officer
Oct 16, 2023 08:30AM Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
Sep 27, 2023 09:09AM Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 5, 2023 08:30AM Allogene Therapeutics Announces Participation in September Investor Conference
Aug 14, 2023 08:30AM Allogene Therapeutics Appoints Earl Douglas as General Counsel
Aug 2, 2023 04:02PM Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Jul 26, 2023 08:30AM Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
Jun 15, 2023 09:30AM Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
Jun 14, 2023 08:01AM Allogene Therapeutics (ALLO) Announces CFO Departure
Jun 14, 2023 08:00AM Allogene Therapeutics Announces Departure of Chief Financial Officer
View More Recent Stories View Older Stories